EMP-012 / Empirico, GSK - LARVOL DELTA

GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases (GSK Press Release) - "The agreement grants GSK full worldwide development and commercial rights to EMP-012. Empirico will continue to lead the clinical development of EMP-012 through the completion of the ongoing phase I clinical trial, following which GSK will assume responsibility for worldwide development, regulatory filings, and commercialisation....siRNA candidate EMP-012 in phase I for treatment of COPD."

Licensing / partnership • Chronic Obstructive Pulmonary Disease • Immunology

A 3-part study consisting of a randomised, double-blind, placebo-controlled, single ascending dose study in healthy participants, followed by an open-labelled single dose LPS-challenge study in healthy participants and an open-labelled multiple dose study in COPD patients to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EMP-012 for Injection Administered... (ANZCTR) - P1 | N=40 | Active, not recruiting | Sponsor: Empirico Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Chronic Obstructive Pulmonary Disease • Immunology • Pulmonary Disease • Respiratory Diseases

A Randomised, Double-Blind, Placebo-Controlled, Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of EMP-012 for Injection Administered Subcutaneously to Healthy Volunteers (ANZCTR) - P1 | N=40 | Recruiting | Sponsor: Empirico Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Jul 2024

Enrollment open • Trial initiation date • Pulmonary Disease • Respiratory Diseases